NO20006285L - Sammensetning som innbefatter et karnitin og glutation som er anvendelig for å öke absorpsjonen av glutation og for å potensiere dets virkninger - Google Patents

Sammensetning som innbefatter et karnitin og glutation som er anvendelig for å öke absorpsjonen av glutation og for å potensiere dets virkninger

Info

Publication number
NO20006285L
NO20006285L NO20006285A NO20006285A NO20006285L NO 20006285 L NO20006285 L NO 20006285L NO 20006285 A NO20006285 A NO 20006285A NO 20006285 A NO20006285 A NO 20006285A NO 20006285 L NO20006285 L NO 20006285L
Authority
NO
Norway
Prior art keywords
glutathione
potentiating
carnitine
absorption
useful
Prior art date
Application number
NO20006285A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006285D0 (no
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of NO20006285D0 publication Critical patent/NO20006285D0/no
Publication of NO20006285L publication Critical patent/NO20006285L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20006285A 1999-04-16 2000-12-11 Sammensetning som innbefatter et karnitin og glutation som er anvendelig for å öke absorpsjonen av glutation og for å potensiere dets virkninger NO20006285L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999RM000230A IT1306130B1 (it) 1999-04-16 1999-04-16 Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti.
PCT/IT2000/000129 WO2000062773A1 (en) 1999-04-16 2000-04-07 Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects

Publications (2)

Publication Number Publication Date
NO20006285D0 NO20006285D0 (no) 2000-12-11
NO20006285L true NO20006285L (no) 2001-02-12

Family

ID=11406677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006285A NO20006285L (no) 1999-04-16 2000-12-11 Sammensetning som innbefatter et karnitin og glutation som er anvendelig for å öke absorpsjonen av glutation og for å potensiere dets virkninger

Country Status (25)

Country Link
US (1) US6306392B1 (xx)
EP (1) EP1087762B1 (xx)
JP (1) JP2002542191A (xx)
KR (1) KR20010071467A (xx)
CN (1) CN1300214A (xx)
AR (1) AR033325A1 (xx)
AT (1) ATE282409T1 (xx)
AU (1) AU774191B2 (xx)
BR (1) BR0006045A (xx)
CA (1) CA2334919C (xx)
DE (1) DE60015893T2 (xx)
EE (1) EE200000732A (xx)
ES (1) ES2232443T3 (xx)
HU (1) HU229272B1 (xx)
IL (1) IL139851A0 (xx)
IS (1) IS5740A (xx)
IT (1) IT1306130B1 (xx)
NO (1) NO20006285L (xx)
NZ (1) NZ509276A (xx)
PL (1) PL213130B1 (xx)
PT (1) PT1087762E (xx)
SK (1) SK18852000A3 (xx)
TN (1) TNSN00077A1 (xx)
TR (1) TR200003688T1 (xx)
WO (1) WO2000062773A1 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306147B1 (it) * 1999-05-28 2001-05-30 Biosalts Srl Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
IT1316998B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
IT1316997B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di vasculopatie,che comprende propionil l-carnitina e coenzima q10.
KR100528720B1 (ko) * 2002-08-29 2005-11-15 주식회사 메디넥스 중금속 제거용 특수 영양식품
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
CA2588709C (en) * 2004-11-24 2015-07-14 Hill's Pet Nutrition, Inc. Use of lipoic acid to improve hepatic clearance of xenobiotic substances
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US8148325B2 (en) 2004-12-30 2012-04-03 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
CA2598792A1 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
RU2377980C2 (ru) 2005-08-17 2010-01-10 Хилл`С Пет Ньютришн, Инк. Способы и композиции для профилактики и лечения заболеваний почек
JP4831540B2 (ja) * 2005-08-26 2011-12-07 株式会社興人 経口催眠剤及び催眠性飲食物
JP2009107962A (ja) * 2007-10-29 2009-05-21 Asahi Breweries Ltd 酵母エキス含有組成物
AU2009315771A1 (en) * 2008-11-11 2010-05-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compound useful for treating cellulite
CN103478718B (zh) * 2013-09-27 2015-10-28 美国东方生物技术（香港）有限公司 提高人体内谷胱甘肽浓度的功能食品及其制备方法
CN103535721B (zh) * 2013-09-27 2016-04-06 美国东方生物技术（香港）有限公司 提高人体内谷胱甘肽浓度的组合物及其制备方法和应用
CN105054068A (zh) * 2014-01-25 2015-11-18 北京凯因科技股份有限公司 一种酵母谷胱甘肽营养配制品
IL261670B (en) * 2018-09-06 2019-06-30 Tudu Holdings Ltd Magnesium-containing formulation and uses thereof
JP7478517B2 (ja) * 2019-04-24 2024-05-07 三菱商事ライフサイエンス株式会社 脂質活性代謝改善組成物
KR102559814B1 (ko) * 2021-05-14 2023-07-26 가톨릭대학교 산학협력단 글루타치온을 유효성분으로 포함하는 신장질환 치료용 약학적 조성물
KR102535328B1 (ko) * 2022-10-18 2023-05-26 주식회사 청안오가닉스 흑후추 추출물을 함유하여 글루타치온의 체내 흡수율을 높인 건강기능 식품용 조성물 및 이의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283951B1 (it) * 1996-03-15 1998-05-07 Mendes Srl Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito

Also Published As

Publication number Publication date
IT1306130B1 (it) 2001-05-30
JP2002542191A (ja) 2002-12-10
HUP0102501A2 (hu) 2001-11-28
PL344790A1 (en) 2001-11-19
EE200000732A (et) 2002-06-17
ITRM990230A1 (it) 2000-10-16
EP1087762A1 (en) 2001-04-04
NZ509276A (en) 2002-09-27
AU774191B2 (en) 2004-06-17
PL213130B1 (pl) 2013-01-31
SK18852000A3 (sk) 2001-06-11
CA2334919A1 (en) 2000-10-26
IS5740A (is) 2000-11-28
AU4311700A (en) 2000-11-02
CN1300214A (zh) 2001-06-20
EP1087762B1 (en) 2004-11-17
WO2000062773A1 (en) 2000-10-26
HU229272B1 (en) 2013-10-28
BR0006045A (pt) 2001-03-13
HUP0102501A3 (en) 2002-12-28
CA2334919C (en) 2009-02-24
PT1087762E (pt) 2005-03-31
IL139851A0 (en) 2002-02-10
US6306392B1 (en) 2001-10-23
DE60015893T2 (de) 2005-12-01
ATE282409T1 (de) 2004-12-15
AR033325A1 (es) 2003-12-17
ES2232443T3 (es) 2005-06-01
DE60015893D1 (de) 2004-12-23
TR200003688T1 (tr) 2001-06-21
TNSN00077A1 (fr) 2002-05-30
NO20006285D0 (no) 2000-12-11
KR20010071467A (ko) 2001-07-28

Similar Documents

Publication Publication Date Title
NO20006285L (no) Sammensetning som innbefatter et karnitin og glutation som er anvendelig for å öke absorpsjonen av glutation og for å potensiere dets virkninger
DE69939605D1 (de) Oral verabreichbare galenische Form enthaltend Metformin und einen Absorptionspromoter
NO20035087L (no) Anvendelse av HMG fragment som anti-inflammatoriske midler
NO20020383D0 (no) Mutilinderivater og deres anvendelse som anti-bakterielle midler
NO992725D0 (no) 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer
PT1147083E (pt) Derivados de arilpiperazinil-ciclohexilindole para o tratamento da depressao
NO20010686L (no) Hydroksypipecolathydroksyaminsyrederivater som MMP inhibitorer
NO20013600L (no) Acylderivater som behandler VLA-4 relaterte lidelser
PT1144395E (pt) Derivados de 2-aminobenzoxazinona para o tratamento da obesidade
NO20014412D0 (no) Forbindelser nyttige som anti-inflammatoriske midler
IL154574A0 (en) Hydroxamate derivatives useful as deacetylase inhibitors
NO20020275L (no) Imidazoimidazoler og -triazoler som anti-inflammatoriske midler
PT1143977E (pt) Derivados de 2-oxibenzoxazinona para o tratamento da obesidade
EE200200617A (et) (Tio)karbamiidi derivaat, seda sisaldav farmatseutiline preparaat, selle valmistamine ning kasutamine VIIa-teguri inhibiitorina
NO984761D0 (no) Aminoisokinoliner og aminotienopyridinderivater og deres anvendelse som antiinflammatoriske midler
DE60034590D1 (de) Doppelflanken-schneckenmechanismus
ITMI991402A0 (it) Composti amorfi e relative composizioni farmaceutiche
NO20010331D0 (no) Ftalazinderivater som fosfodiesterase 4-inhibitorer
NO20030233L (no) Fremgangsmåte for å finne forbindelser som er egnet for behandling og/ellerprofylakse av fedme
DK1086097T3 (da) Sulfonylbenzenforbindelser som anti-inflammatoriske/analgetiske midler
ATE313322T1 (de) Synergistische kombination: gabapentin und pregabalin
DK1173436T3 (da) Thiazolidindionderivat og anvendelse deraf som antidiabetikum
PT1263421E (pt) Avasimibe, o inibidor duplo da sintese de ester de colesterilo e de ester ceroso, para o tratamento de disturbios da glandula sebacea
NO20001200D0 (no) Pyrrolopyrrolonderivater som inhibitorer av neurofil elastase
NO20000094L (no) 6-Azaurcilderivater som IL-5 inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application